...Thus, clinical development of ocular therapeutics is impeded in the EU due to poor collaboration among academic and industry scientists.3D-NET establishes a network of industry (Gadea, KalVista & RenaSci) and academic partners (UCD & UVA), who exchange knowledge and people, and who’s combined S&T expertise will enhance the discovery and development of drugs that target ocular pathologies (retinal ...